Myasthenia gravis (MG) treatment: pyridostigmine
Evidence-based neurology checklist on myasthenia gravis (mg) treatment: pyridostigmine: Efficacy Pyridostigmine showed better efficacy than placebo in a randomized control trial Dosing regime Precautions Side effects Treatment of side effects
Efficacy
- Pyridostigmine showed better efficacy than placebo in a randomized control trial
Dosing regime
Precautions
Side effects
Treatment of side effects
References
- Skeie GO, Apostolski S, Evoli A, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol 2010; 17:893-902.
- Sanders DB, Wolfe GI, Benatar M, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology 2016; 87:419-425.
- Remijn-Nelissen L, Bakker WR, van den Hout WB, et al. Efficacy of pyridostigmine in myasthenia gravis: a randomized, double-blind, placebo-controlled crossover trial. Neurology 2026; 106:e214865.
- Donskov AO, Vinge L, Axelsen SM, Andersen H. Overactive bladder in patients with myasthenia gravis-A cross-sectional population-based study. Acta Neurol Scand 2021; 144:76-80.
- Ceccanti M, Libonati L, Ruffolo G, et al. Effects of 3,4-diaminopyridine on myasthenia gravis: Preliminary results of an open-label study. Front Pharmacol 2022; 13:982434.
Related checklists
- Myasthenia gravis (MG) treatment: steroids
- Myasthenia gravis (MG): non-steroid immunosuppression: indications
- Myasthenia gravis (MG): non-steroid immunosuppression: agents
- Myasthenia gravis (MG): investigational treatments
- Thymectomy for non-thymoma myasthenia gravis (MG)
- Myasthenia gravis (MG): rehabilitation
- Myasthenia gravis (MG) and anaesthesia
